These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

728 related articles for article (PubMed ID: 21866545)

  • 21. Comparison of plasma Epstein-Barr virus (EBV) DNA levels and serum EBV immunoglobulin A/virus capsid antigen antibody titers in patients with nasopharyngeal carcinoma.
    Shao JY; Li YH; Gao HY; Wu QL; Cui NJ; Zhang L; Cheng G; Hu LF; Ernberg I; Zeng YX
    Cancer; 2004 Mar; 100(6):1162-70. PubMed ID: 15022282
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Plasma Macrophage Migration Inhibitory Factor and CCL3 as Potential Biomarkers for Distinguishing Patients with Nasopharyngeal Carcinoma from High-Risk Individuals Who Have Positive Epstein-Barr Virus Capsid Antigen-Specific IgA.
    Xue N; Lin JH; Xing S; Liu D; Li SB; Lai YZ; Wang XP; Mao MJ; Zhong Q; Zeng MS; Liu WL
    Cancer Res Treat; 2019 Jan; 51(1):378-390. PubMed ID: 29807404
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Combining Epstein-Barr virus antibodies for early detection of nasopharyngeal carcinoma: A meta-analysis.
    Lian M
    Auris Nasus Larynx; 2023 Jun; 50(3):430-439. PubMed ID: 36241564
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Complementary serum test of antibodies to Epstein-Barr virus nuclear antigen-1 and early antigen: a possible alternative for primary screening of nasopharyngeal carcinoma.
    Chang KP; Hsu CL; Chang YL; Tsang NM; Chen CK; Lee TJ; Tsao KC; Huang CG; Chang YS; Yu JS; Hao SP
    Oral Oncol; 2008 Aug; 44(8):784-92. PubMed ID: 18206420
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation of seven recombinant VCA-IgA ELISA kits for the diagnosis of nasopharyngeal carcinoma in China: a case-control trial.
    Gao R; Wang L; Liu Q; Zhang LF; Ye YF; Xie SH; Du JL; Chen SH; Guo J; Yang MJ; Lin CY; Cao SM
    BMJ Open; 2017 Jul; 7(6):e013211. PubMed ID: 28674124
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Proper use of serum antibody titres against Epstein-Barr virus in nasopharyngeal carcinoma: IgA/virus capsid antigen for diagnosis and EBV-related nuclear antigen-2 for follow-up.
    Shimakage M; Dezawa T; Chatani M
    Acta Otolaryngol; 2000 Jan; 120(1):100-4. PubMed ID: 10779195
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Chemokine CCL27 is a novel plasma biomarker for identification the nasopharyngeal carcinoma patients from the Epstein-Barr virus capsid antigen-specific IgA seropositive population.
    Mao MJ; Xue N; Wang XP; Chi PD; Liu YJ; Huang Q; Dai SQ; Liu WL
    BMC Cancer; 2018 Jan; 18(1):9. PubMed ID: 29295705
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of three different serological techniques for primary diagnosis and monitoring of nasopharyngeal carcinoma in two age groups from Tunisia.
    Karray H; Ayadi W; Fki L; Hammami A; Daoud J; Drira MM; Frikha M; Jlidi R; Middeldorp JM
    J Med Virol; 2005 Apr; 75(4):593-602. PubMed ID: 15714486
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Autoantibody Signatures Combined with Epstein-Barr Virus Capsid Antigen-IgA as a Biomarker Panel for the Detection of Nasopharyngeal Carcinoma.
    Peng YH; Xu YW; Huang LS; Zhai TT; Dai LH; Qiu SQ; Yang YS; Chen WZ; Zhang LQ; Li EM; Xu LY
    Cancer Prev Res (Phila); 2015 Aug; 8(8):729-36. PubMed ID: 25990085
    [TBL] [Abstract][Full Text] [Related]  

  • 30. EBV specific antibody-based and DNA-based assays in serologic diagnosis of nasopharyngeal carcinoma.
    Chan KH; Gu YL; Ng F; Ng PS; Seto WH; Sham JS; Chua D; Wei W; Chen YL; Luk W; Zong YS; Ng MH
    Int J Cancer; 2003 Jul; 105(5):706-9. PubMed ID: 12740922
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognostic value of serum Epstein-Barr virus antibodies in patients with nasopharyngeal carcinoma and undetectable pretreatment Epstein-Barr virus DNA.
    Yao JJ; Lin L; Jin YN; Wang SY; Zhang WJ; Zhang F; Zhou GQ; Cheng ZB; Qi ZY; Sun Y
    Cancer Sci; 2017 Aug; 108(8):1640-1647. PubMed ID: 28603915
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Two-step Epstein-Barr virus immunoglobulin A enzyme-linked immunosorbent assay system for serological screening and confirmation of nasopharyngeal carcinoma.
    Paramita DK; Fachiroh J; Haryana SM; Middeldorp JM
    Clin Vaccine Immunol; 2009 May; 16(5):706-11. PubMed ID: 19321695
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Enhancing the efficiency of Epstein-Barr viral serologic test in the diagnosis of nasopharyngeal carcinoma.
    Zhang C; Zong Y; Huang B; Sun Y; Ye Y; Feng K; Li J; Zhang F
    Zhonghua Zhong Liu Za Zhi; 2002 Jul; 24(4):356-9. PubMed ID: 12408763
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rta-IgG as a biomarker for diagnosis and post treatment prognostic of nasopharyngeal carcinoma.
    Xu XF; Lu RQ; Xiao R; Zhou L; Zhao XM; Hu XC; Gao X; Guo L
    Cancer Biomark; 2016; 16(3):467-76. PubMed ID: 27062704
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Epstein-Barr virus glycoprotein gH/gL antibodies complement IgA-viral capsid antigen for diagnosis of nasopharyngeal carcinoma.
    Li RC; Du Y; Zeng QY; Tang LQ; Zhang H; Li Y; Liu WL; Zhong Q; Zeng MS; Huang XM
    Oncotarget; 2016 Mar; 7(13):16372-83. PubMed ID: 27093005
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Assessment of the Long-term Diagnostic Performance of a New Serological Screening Scheme in Large-scale Nasopharyngeal Carcinoma Screening.
    Yu X; Ji M; Cheng W; Wu B; Du Y; Cao S
    J Cancer; 2018; 9(12):2093-2097. PubMed ID: 29937927
    [No Abstract]   [Full Text] [Related]  

  • 37. Cigarette smoking increases the risk of nasopharyngeal carcinoma through the elevated level of IgA antibody against Epstein-Barr virus capsid antigen: A mediation analysis.
    Hsu WL; Chien YC; Huang YT; Yu KJ; Ko JY; Lin CY; Tsou YA; Leu YS; Liao LJ; Chang YL; Su JY; Liu Z; Wang CP; Terng SD; Hua CH; Lee JC; Yang TL; Kate Hsiao CH; Wu MS; Tsai MH; Liu MJ; Lou PJ; Hildesheim A; Chen CJ;
    Cancer Med; 2020 Mar; 9(5):1867-1876. PubMed ID: 31925935
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical performance of a prefabricated immunofluorescence assay for nasopharyngeal cancer screening.
    Chen VHE; Ong L; Teo WK; Siow CH; Goh HL; Tan C; Lim WS; Eu D; Cheong ISY; Chan SH; Loh KS; Tay JK
    Head Neck; 2024 Sep; 46(9):2223-2232. PubMed ID: 38817018
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Multiparametric Detection of Antibodies against Different EBV Antigens to Predict Risk for Nasopharyngeal Carcinoma in a High-Risk Population of China.
    Chen H; Chen S; Lu J; Wang X; Li J; Li L; Fu J; Scheper T; Meyer W; Peng YH; Liu W
    Cancer Prev Res (Phila); 2017 Sep; 10(9):542-550. PubMed ID: 28754665
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluation of Epstein-Barr virus antigen-based immunoassays for serological diagnosis of nasopharyngeal carcinoma.
    Tang JW; Rohwäder E; Chu IM; Tsang RK; Steinhagen K; Yeung AC; To KF; Chan PK
    J Clin Virol; 2007 Dec; 40(4):284-8. PubMed ID: 17977062
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 37.